k141_150282_17	SARG|HE999704.1.gene3064.p01	30.4	204	463	241	4.30e-16	76.6
k141_150282_17	SARG|gi|441475675|emb|CCQ25429.1|	33.3	120	463	211	2.65e-11	62.0
k141_25101_24	SARG|P42332	29.0	290	288	306	1.05e-30	115
k141_25101_24	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.0	290	288	306	1.05e-30	115
k141_25101_24	SARG|gi|510143239|gb|AGN36970.1|	29.0	290	288	313	1.21e-30	115
k141_25101_24	SARG|ABB80128	29.0	290	288	306	1.47e-30	115
k141_25101_24	SARG|gi|447195835|ref|WP_001273091.1|	29.9	294	288	306	1.47e-30	115
k141_25101_24	SARG|gi|447195836|ref|WP_001273092.1|	29.6	294	288	306	3.98e-30	114
k141_25101_24	SARG|ZP_04081918	32.0	222	288	306	7.74e-30	113
k141_25101_24	SARG|gi|542061059|gb|ERI11611.1|	31.7	221	288	316	1.81e-29	112
k141_25101_24	SARG|gi|500448961|gb|EOP61695.1|	28.3	297	288	306	2.91e-29	112
k141_25101_24	SARG|gi|446026113|ref|WP_000103968.1|	30.9	217	288	306	5.65e-29	111
k141_25101_34	SARG|YP_002333394	33.9	118	388	323	7.93e-12	64.7
k141_25101_34	SARG|AF310956.2.gene5.p01	33.1	118	388	323	2.56e-11	63.2
k141_25101_34	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	33.1	118	388	323	2.56e-11	63.2
k141_25101_34	SARG|gb|AAB05626.1|ARO:3002943|vanHB	32.2	118	388	323	4.58e-11	62.4
k141_25101_34	SARG|Q47748	32.2	118	388	323	8.21e-11	61.6
k141_25101_34	SARG|gi|498515089|ref|WP_010815296.1|	32.2	118	388	323	1.47e-10	60.8
k141_25101_34	SARG|gi|985522333|ref|WP_060811962.1|	32.2	118	388	323	1.97e-10	60.5
k141_41790_10	SARG|gb|CAE00499.1|ARO:3003835|cdeA	30.9	427	433	441	1.91e-60	202
k141_25142_18	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	25.6	195	1048	722	3.23e-15	79.3
k141_154539_37	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	28.5	186	438	397	1.88e-16	79.7
k141_154539_39	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	32.6	236	458	370	1.39e-26	109
k141_154539_39	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	248	458	381	6.59e-25	104
k141_154539_39	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	248	458	381	6.59e-25	104
k141_154539_39	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.8	248	458	381	1.22e-24	103
k141_154539_39	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.9	244	458	381	1.22e-24	103
k141_154539_39	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.8	248	458	381	1.22e-24	103
k141_154539_39	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	244	458	381	1.22e-24	103
k141_154539_39	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.2	279	458	367	1.89e-24	103
k141_154539_39	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.2	279	458	368	1.91e-24	103
k141_154539_39	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.8	238	458	365	6.28e-24	101
k141_154539_40	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	48.1	231	231	235	2.21e-76	229
k141_154539_40	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	47.4	228	231	233	9.64e-75	225
k141_154539_40	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.2	225	231	231	5.95e-73	220
k141_154539_40	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	46.7	225	231	229	1.12e-72	219
k141_154539_40	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.9	227	231	232	2.85e-71	216
k141_154539_40	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.9	227	231	232	2.85e-71	216
k141_154539_40	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	46.5	226	231	231	3.91e-71	216
k141_154539_40	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	46.1	230	231	239	5.04e-71	216
k141_154539_40	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	45.8	225	231	232	8.10e-71	215
k141_154539_40	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	46.7	227	231	231	3.17e-70	213
k141_158946_12	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	39.5	162	164	166	2.35e-29	104
k141_158946_12	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	45.8	144	164	167	3.41e-29	104
k141_158946_12	SARG|gb|CBL80435.1|ARO:3002869|dfrK	34.8	164	164	163	5.45e-27	98.6
k141_158946_12	NCBI|WP_031775848.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	34.8	164	164	163	5.45e-27	98.6
k141_158946_12	NCBI|WP_012779617.1|1|1|dfrK|dfrK|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrK|AMR|diaminopyrimidine	35.5	169	164	163	1.53e-26	97.4
k141_158946_12	SARG|gb|BAE15963.1|ARO:3002868|dfrG	35.7	168	164	165	1.80e-25	94.7
k141_158946_12	SARG|gb|CAF31623.1|ARO:3005354|dfr22	38.6	132	164	165	2.22e-23	89.4
k141_158946_12	NCBI|WP_063844370.1|1|1|dfrA22|dfrA22|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA22|AMR|diaminopyrimidine	38.6	132	164	165	6.21e-23	88.2
k141_158946_12	SARG|CAX16467	38.2	131	164	165	1.23e-22	87.4
k141_158946_12	NCBI|WP_071846242.1|1|1|dfrA33|dfrA33|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA33|AMR|diaminopyrimidine	38.2	131	164	165	1.74e-22	87.0
k141_158946_26	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.5	228	233	231	4.60e-60	187
k141_158946_26	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.1	230	233	232	8.70e-58	182
k141_158946_26	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.1	230	233	232	8.70e-58	182
k141_158946_26	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.5	228	233	232	1.74e-57	181
k141_158946_26	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.1	232	233	231	3.39e-57	180
k141_158946_26	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.1	232	233	231	3.39e-57	180
k141_158946_26	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.2	232	233	231	2.72e-56	178
k141_158946_26	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.7	230	233	233	8.18e-56	177
k141_158946_26	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.5	233	233	231	2.18e-55	176
k141_158946_26	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.9	233	233	229	2.91e-55	175
k141_158946_31	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	28.1	210	214	550	2.17e-17	79.0
k141_158946_31	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.0	235	214	648	4.59e-14	69.3
k141_158946_31	SARG|gb|WP_096809342.1|ARO:3007029|salE	28.0	200	214	543	1.01e-11	62.4
k141_158946_31	SARG|AXF35727.1	24.1	195	214	497	1.20e-09	56.2
k141_158946_31	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	25.1	207	214	568	5.60e-09	54.3
k141_158946_31	SARG|gb|AVI44920.1|ARO:3004470|poxtA	25.1	171	214	542	1.82e-08	52.8
k141_158946_31	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	25.1	171	214	544	1.83e-08	52.8
k141_158946_31	SARG|U82085.gene.p01	25.5	208	214	552	1.83e-08	52.8
k141_158946_31	ResF|poxtA-Ef_1_WP094899500.1_1	24.7	190	214	538	1.97e-07	49.7
k141_158946_31	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	24.7	190	214	543	1.98e-07	49.7
k141_158946_59	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	39.7	219	221	255	1.76e-59	186
k141_158946_59	SARG|gi|657888313|ref|WP_029592374.1|	46.6	219	221	648	3.22e-57	190
k141_158946_59	SARG|gi|696368937|ref|WP_032943949.1|	46.1	219	221	648	3.22e-57	190
k141_158946_59	SARG|gi|851913025|ref|WP_048215946.1|	46.1	219	221	648	3.22e-57	190
k141_158946_59	SARG|YP_002850060	46.1	219	221	648	3.22e-57	190
k141_158946_59	SARG|gi|489930965|ref|WP_003834285.1|	46.1	219	221	648	3.22e-57	190
k141_158946_59	SARG|gi|696361545|ref|WP_032936694.1|	46.1	219	221	648	4.48e-57	190
k141_158946_59	SARG|gi|489936909|ref|WP_003840216.1|	46.1	219	221	648	4.48e-57	190
k141_158946_59	SARG|gi|507079862|ref|WP_016150620.1|	46.1	219	221	648	4.48e-57	190
k141_158946_59	SARG|gi|949791377|ref|WP_057104572.1|	46.1	219	221	648	4.48e-57	190
k141_158946_61	CARD|gb|AAC73788.1|ARO:3003841|kdpE	32.5	228	224	225	4.90e-31	112
k141_158946_61	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	34.6	228	224	232	5.80e-31	112
k141_158946_61	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	34.6	228	224	232	5.80e-31	112
k141_158946_61	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	32.4	225	224	225	1.92e-30	111
k141_158946_61	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.0	227	224	232	6.28e-30	110
k141_158946_61	SARG|ZP_02848503	30.9	223	224	221	5.24e-29	107
k141_158946_61	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	219	3.84e-28	105
k141_158946_61	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	220	3.93e-28	105
k141_158946_61	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	219	5.39e-28	104
k141_158946_61	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	221	224	220	5.52e-28	104
k141_158946_62	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.6	217	418	885	4.75e-14	73.2
k141_158946_82	SARG|gi|686113687|ref|WP_031764317.1|	24.8	266	448	451	4.64e-15	75.9
k141_59103_4	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	44.8	683	646	703	5.07e-176	516
k141_59103_18	CARD|gb|BAB36671.1|ARO:3000832|evgA	31.7	208	215	204	1.24e-30	110
k141_59103_18	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.0	113	215	228	1.93e-09	54.7
k141_59103_18	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.4	112	215	223	1.63e-08	52.0
k141_59103_18	CARD|gb|ATC67679.1|ARO:3000838|arlR	26.5	166	215	219	2.15e-08	51.6
k141_59103_18	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.0	110	215	231	3.12e-06	45.4
k141_29983_2	SARG|ZP_02848503	32.4	111	258	221	4.84e-08	51.2
k141_13167_21	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.6	232	303	307	4.49e-17	79.0
k141_13167_24	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.4	239	358	258	1.72e-30	115
k141_13167_24	SARG|gi|895865878|ref|WP_048974758.1|	32.3	220	358	646	6.82e-23	99.0
k141_13167_24	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.0	214	358	664	5.37e-17	81.3
k141_13167_24	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.8	205	358	362	8.57e-16	76.6
k141_13167_24	SARG|gb|AAK76136.1|ARO:3000025|patB	26.5	211	358	588	4.00e-14	72.4
k141_13167_24	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.6	232	358	579	5.29e-14	72.0
k141_13167_24	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.2	232	358	579	1.68e-13	70.5
k141_13167_24	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	216	358	655	3.21e-13	69.7
k141_13167_24	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	216	358	655	3.21e-13	69.7
k141_13167_24	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.3	216	358	655	7.63e-13	68.6
k141_13167_30	SARG|gb|CDO61516.1|ARO:3003949|efrB	54.0	326	618	362	2.19e-115	347
k141_13167_30	SARG|gb|AAK76136.1|ARO:3000025|patB	36.5	581	618	588	5.90e-113	349
k141_13167_30	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.7	515	618	664	1.26e-103	327
k141_13167_30	SARG|gi|748767925|ref|WP_040019608.1|	38.1	517	618	623	1.33e-86	281
k141_13167_30	SARG|gi|702897513|ref|WP_033300957.1|	38.0	510	618	601	2.15e-86	280
k141_13167_30	SARG|gi|928900436|ref|WP_053931243.1|	35.1	513	618	600	2.93e-86	280
k141_13167_30	SARG|gi|664579989|ref|WP_031094015.1|	35.1	513	618	601	3.01e-86	280
k141_13167_30	SARG|gi|655413091|ref|WP_028811890.1|	35.0	606	618	603	4.66e-85	276
k141_13167_30	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.0	528	618	582	5.47e-85	276
k141_13167_30	SARG|gi|947982677|ref|WP_056642336.1|	32.5	604	618	626	5.75e-85	277
k141_13167_31	SARG|gb|WP_104671188.1|ARO:3003948|efrA	42.5	525	724	575	2.50e-132	402
k141_13167_31	SARG|gb|AAK76137.1|ARO:3000024|patA	36.8	517	724	564	1.67e-106	335
k141_13167_31	SARG|gi|558888514|ref|WP_023543283.1|	32.5	486	724	615	3.91e-66	229
k141_13167_31	SARG|AF170880.4.gene1.p01	32.5	486	724	615	5.41e-66	228
k141_13167_31	SARG|gi|662129758|ref|WP_030081404.1|	31.6	484	724	605	1.14e-64	224
k141_13167_31	SARG|gi|695842130|ref|WP_032755430.1|	31.9	486	724	603	1.51e-64	224
k141_13167_31	SARG|gi|505420018|ref|WP_015607120.1|	31.9	486	724	603	1.51e-64	224
k141_13167_31	SARG|gi|664085850|ref|WP_030624018.1|	31.6	484	724	605	1.57e-64	224
k141_13167_31	SARG|gi|926400371|ref|WP_053728483.1|	31.5	485	724	603	3.98e-64	223
k141_13167_31	SARG|gi|664180077|ref|WP_030714054.1|	31.4	484	724	605	5.72e-64	223
k141_180026_22	CARD|gb|AAA99503.1|ARO:3003250|bcrC	35.0	103	176	203	1.13e-11	59.7
k141_180026_54	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.4	223	231	229	7.69e-63	194
k141_180026_54	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.1	227	231	231	9.35e-62	192
k141_180026_54	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.1	227	231	231	1.87e-61	191
k141_180026_54	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.1	227	231	231	5.32e-61	190
k141_180026_54	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.5	228	231	232	7.77e-61	189
k141_180026_54	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	44.5	227	231	231	1.51e-60	189
k141_180026_54	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.0	229	231	233	1.61e-60	189
k141_180026_54	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.1	228	231	232	2.21e-60	188
k141_180026_54	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.2	226	231	232	6.26e-60	187
k141_180026_54	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	44.4	223	231	230	2.37e-59	186
k141_180026_55	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.0	270	484	370	1.15e-25	107
k141_180026_55	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.8	306	484	392	3.22e-24	103
k141_180026_62	SARG|ABV82118	24.6	439	604	639	5.95e-28	117
k141_180026_62	SARG|gi|1004359922|gb|AMP42228.1|	26.7	454	604	639	5.95e-28	117
k141_180026_62	SARG|ABN79417	26.4	455	604	639	1.06e-27	117
k141_180026_62	SARG|ZP_03989103	24.5	458	604	639	1.06e-27	117
k141_180026_62	SARG|ABV82120	24.5	458	604	639	1.06e-27	117
k141_180026_62	SARG|AAO42740	26.4	455	604	639	1.41e-27	116
k141_180026_62	SARG|AY485126.gene.p01	26.4	455	604	639	1.41e-27	116
k141_180026_62	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	455	604	639	1.41e-27	116
k141_180026_62	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	455	604	629	1.81e-27	116
k141_180026_62	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	455	604	629	1.81e-27	116
k141_180026_155	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.9	496	518	655	1.24e-88	284
k141_180026_155	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	496	518	655	1.74e-88	284
k141_180026_155	SARG|gb|AKA86814|ARO:3003746|optrA	33.7	496	518	655	1.74e-88	284
k141_180026_155	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.9	496	518	655	2.44e-88	283
k141_180026_155	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	496	518	655	4.79e-88	283
k141_180026_155	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	496	518	655	4.79e-88	283
k141_180026_155	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	496	518	655	4.79e-88	283
k141_180026_155	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	496	518	655	6.72e-88	282
k141_180026_155	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.7	496	518	655	9.42e-88	282
k141_180026_155	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	496	518	655	3.64e-87	280
k141_180026_170	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	30.9	162	941	633	1.40e-15	80.1
k141_180026_188	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	57.9	159	160	159	1.47e-58	178
k141_180026_211	CARD|gb|AAG06465.1|ARO:3005063|cprR	28.3	113	354	223	2.27e-10	58.9
k141_180026_211	CARD|gb|BAB36671.1|ARO:3000832|evgA	31.3	115	354	204	8.18e-07	48.1
k141_180026_276	SARG|YP_002937728	97.6	289	290	289	1.02e-198	543
k141_180026_276	SARG|ZP_03958019	65.7	280	290	317	1.95e-126	362
k141_180026_276	SARG|ZP_04528247	64.2	285	290	279	3.95e-117	337
k141_180026_276	SARG|YP_002929946	58.5	282	290	282	9.21e-107	310
k141_180026_276	SARG|ZP_03984017	56.7	277	290	288	1.62e-96	285
k141_180026_276	SARG|ZP_04433866	56.3	277	290	288	3.26e-96	284
k141_180026_276	SARG|ZP_03949893	56.3	277	290	288	3.26e-96	284
k141_180026_276	SARG|ZP_03941859	51.8	280	290	288	1.04e-84	254
k141_180026_276	SARG|ZP_03938934	51.8	280	290	288	1.04e-84	254
k141_180026_276	SARG|ZP_03916453	46.3	287	290	290	6.08e-79	240
k141_13322_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	48.0	229	234	228	1.39e-71	217
k141_13322_14	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.6	227	234	231	2.95e-61	191
k141_13322_14	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.2	232	234	232	7.91e-59	184
k141_13322_14	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.2	232	234	232	7.91e-59	184
k141_13322_14	CARD|gb|ATC67679.1|ARO:3000838|arlR	43.1	225	234	219	2.14e-58	183
k141_13322_14	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	227	234	232	1.27e-57	181
k141_13322_14	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.4	235	234	235	7.91e-57	179
k141_13322_14	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.6	233	234	233	1.05e-56	179
k141_13322_14	CARD|gb|AAD51348.1|ARO:3003066|smeR	42.6	235	234	229	1.32e-56	179
k141_13322_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.5	233	234	231	1.60e-55	176
k141_13322_15	CARD|gb|AAD51347.1|ARO:3003067|smeS	29.5	278	480	467	5.13e-38	143
k141_13322_15	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.7	248	480	381	4.70e-34	130
k141_13322_15	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.7	248	480	381	4.70e-34	130
k141_13322_15	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	248	480	381	2.69e-31	123
k141_13322_15	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	248	480	381	2.69e-31	123
k141_13322_15	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.9	244	480	381	6.93e-31	122
k141_13322_15	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.9	244	480	381	6.93e-31	122
k141_13322_15	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.0	250	480	381	4.57e-30	119
k141_13322_15	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.0	250	480	381	4.57e-30	119
k141_13322_15	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	244	480	381	8.56e-30	119
k141_167984_25	SARG|gb|ADZ12699.1|ARO:3005091|RanA	31.4	191	357	258	4.20e-24	98.6
k141_167984_25	SARG|AAG08983	25.4	201	357	524	6.47e-10	59.3
k141_138693_6	SARG|gi|488374619|ref|WP_002444004.1|	22.3	412	454	452	1.17e-29	119
k141_138693_31	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.9	459	531	654	1.09e-33	134
k141_138693_31	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.9	459	531	670	1.17e-33	134
k141_138693_31	SARG|AAB51122	25.9	459	531	670	1.17e-33	134
k141_138693_31	SARG|Q08425	25.9	459	531	641	1.85e-33	133
k141_138693_31	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.9	459	531	657	2.00e-33	133
k141_138693_31	SARG|Z21523.gene.p01	25.9	459	531	657	2.00e-33	133
k141_138693_31	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.6	464	531	641	2.01e-32	130
k141_138693_31	SARG|AAZ79478	25.6	464	531	657	2.16e-32	130
k141_138693_31	SARG|Q52360	25.9	452	531	641	2.16e-31	127
k141_138693_31	SARG|P70882	25.9	452	531	641	2.16e-31	127
k141_59684_9	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	49.3	219	224	223	9.43e-76	227
k141_59684_9	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	224	219	6.39e-34	120
k141_59684_9	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	224	219	9.01e-34	119
k141_59684_9	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	224	220	9.24e-34	119
k141_59684_9	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.3	220	224	220	1.30e-33	119
k141_59684_9	SARG|ZP_02848503	32.3	220	224	221	2.90e-32	115
k141_59684_9	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	30.4	227	224	231	1.03e-31	114
k141_59684_9	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	30.4	227	224	231	7.96e-31	112
k141_59684_9	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.8	224	224	231	2.21e-30	111
k141_59684_9	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.1	219	224	229	4.16e-30	110
k141_59684_10	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	39.6	280	357	341	3.24e-59	193
k141_59684_10	CARD|gb|AAC75429.1|ARO:3000833|evgS	25.6	172	357	1197	1.63e-11	64.7
k141_59684_10	CARD|gb|ABD30512.1|ARO:3000839|arlS	24.5	249	357	451	4.10e-07	50.4
k141_59684_12	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.3	218	234	293	3.44e-33	120
k141_59684_12	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.9	225	234	307	8.27e-22	90.5
k141_59684_12	SARG|gi|447195835|ref|WP_001273091.1|	29.0	238	234	306	4.16e-21	88.6
k141_59684_12	SARG|ZP_04081918	29.0	238	234	306	7.97e-21	87.8
k141_59684_12	SARG|gi|447195836|ref|WP_001273092.1|	29.0	238	234	306	7.97e-21	87.8
k141_59684_12	SARG|gi|500465078|gb|EOP76697.1|	27.6	228	234	306	1.10e-20	87.4
k141_59684_12	SARG|gi|500448961|gb|EOP61695.1|	27.6	228	234	306	1.53e-20	87.0
k141_59684_12	SARG|gi|445996719|ref|WP_000074574.1|	27.4	234	234	309	1.59e-20	87.0
k141_59684_12	SARG|gi|445996710|ref|WP_000074565.1|	27.4	234	234	309	4.19e-20	85.9
k141_59684_12	SARG|gi|445996722|ref|WP_000074577.1|	27.8	234	234	309	4.19e-20	85.9
k141_59684_14	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	51.2	250	256	255	7.92e-88	260
k141_59684_14	SARG|gi|502669352|ref|WP_012905216.1|	40.3	221	256	648	1.10e-55	187
k141_59684_14	SARG|gi|507086196|ref|WP_016156937.1|	39.8	221	256	648	1.53e-55	187
k141_59684_14	SARG|gi|922960663|ref|WP_053388845.1|	39.4	221	256	648	4.11e-55	186
k141_59684_14	SARG|gi|757799695|ref|WP_043016897.1|	39.4	221	256	648	5.72e-55	186
k141_59684_14	SARG|gi|1045891604|ref|WP_065554100.1|	39.4	221	256	648	5.72e-55	186
k141_59684_14	SARG|gi|507082903|ref|WP_016153652.1|	39.4	221	256	648	5.72e-55	186
k141_59684_14	SARG|gi|740856590|ref|WP_038641842.1|	39.4	221	256	648	5.72e-55	186
k141_59684_14	SARG|gi|835233765|ref|WP_047410073.1|	39.4	221	256	648	1.11e-54	185
k141_59684_14	SARG|gi|754951242|ref|WP_042307417.1|	39.4	221	256	648	1.11e-54	185
k141_59684_15	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	25.3	680	680	641	1.10e-42	162
k141_59684_35	CARD|gb|AAK37618.1|ARO:3005008|TxR	24.6	297	594	318	3.17e-16	79.0
k141_59684_40	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	31.2	253	330	314	8.29e-33	122
k141_59684_40	SARG|AAD51059	33.1	254	330	323	3.72e-32	121
k141_59684_40	SARG|AAD41881	33.5	254	330	323	3.72e-32	121
k141_59684_40	SARG|AAR37059	33.5	254	330	323	1.00e-31	120
k141_59684_40	SARG|AY082011.1.gene6.p01	32.7	254	330	323	2.70e-31	119
k141_59684_40	SARG|gi|552942232|ref|WP_023043160.1|	32.7	254	330	323	3.75e-31	118
k141_59684_40	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	31.1	254	330	323	1.40e-30	117
k141_59684_40	SARG|AAD42183	33.1	254	330	322	1.91e-30	116
k141_59684_40	SARG|gb|AAB05626.1|ARO:3002943|vanHB	31.4	255	330	323	1.00e-29	114
k141_59684_40	SARG|DQ018711.1.gene4.p01	30.3	254	330	322	1.37e-29	114
k141_59684_53	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.5	267	368	355	7.49e-20	88.6
k141_59684_53	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	28.5	267	368	355	7.49e-20	88.6
k141_59684_53	SARG|ACM47285	28.5	267	368	363	8.10e-20	88.6
k141_59684_53	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.1	292	368	355	1.38e-19	87.8
k141_59684_53	SARG|BAE96115	27.1	292	368	355	1.38e-19	87.8
k141_59684_53	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	32.1	193	368	209	6.71e-19	83.2
k141_59684_53	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	26.6	289	368	346	7.95e-19	85.5
k141_59684_53	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.1	281	368	356	1.82e-17	81.6
k141_59684_53	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.4	281	368	356	2.46e-17	81.3
k141_59684_53	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	33.0	182	368	356	4.50e-17	80.5
k141_39264_9	SARG|gb|WP_104671188.1|ARO:3003948|efrA	23.8	227	258	575	9.72e-15	72.4
k141_39264_9	SARG|gi|1033151784|ref|WP_064457526.1|	27.7	202	258	614	9.98e-15	72.4
k141_39264_9	SARG|gi|987887954|ref|WP_060953374.1|	27.7	202	258	614	9.98e-15	72.4
k141_39264_9	SARG|gi|664304639|ref|WP_030834011.1|	27.7	202	258	614	9.98e-15	72.4
k141_39264_9	SARG|gi|1011069317|ref|WP_062010695.1|	27.7	202	258	614	9.98e-15	72.4
k141_39264_9	SARG|gi|827013130|ref|WP_047175495.1|	27.1	207	258	603	1.80e-14	71.6
k141_39264_9	SARG|gi|517787730|ref|WP_018957938.1|	26.6	207	258	610	2.44e-14	71.2
k141_39264_9	SARG|gi|664170108|ref|WP_030704355.1|	26.2	202	258	603	3.28e-14	70.9
k141_39264_9	SARG|gi|501350226|ref|WP_012381861.1|	26.2	202	258	603	3.28e-14	70.9
k141_39264_9	SARG|gi|695891735|ref|WP_032792824.1|	26.6	207	258	603	3.28e-14	70.9
k141_39264_29	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	33.9	186	289	246	2.68e-24	97.4
k141_39264_29	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	33.8	219	289	243	9.45e-23	93.2
k141_39264_29	SARG|BAD86539	29.3	215	289	244	1.34e-22	92.8
k141_39264_29	SARG|L22689.1.gene1.p01	30.1	256	289	257	4.32e-20	86.3
k141_39264_29	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	34.0	159	289	301	4.17e-16	75.9
k141_39264_29	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	33.3	159	289	301	5.70e-16	75.5
k141_39264_29	megares|MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42_1	33.3	159	289	303	5.81e-16	75.5
k141_39264_29	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	28.5	214	289	304	3.77e-15	73.2
k141_72403_19	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	27.5	218	368	568	1.37e-12	67.8
k141_72403_19	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.9	226	368	550	3.07e-10	60.5
k141_72403_19	SARG|gi|686436876|ref|WP_031922735.1|	23.3	210	368	491	2.78e-09	57.4
k141_72403_19	SARG|gi|686444151|ref|WP_031925491.1|	22.9	210	368	488	3.57e-08	53.9
k141_72403_19	SARG|gi|581672381|gb|EVQ77821.1|	22.4	210	368	394	4.05e-08	53.5
k141_72403_19	SARG|gi|587321226|gb|EWW03298.1|	22.4	210	368	413	4.21e-08	53.5
k141_72403_19	SARG|gi|580336413|gb|EVD62957.1|	22.4	210	368	478	4.68e-08	53.5
k141_72403_19	SARG|YP_001569068	22.4	210	368	488	4.74e-08	53.5
k141_72403_19	SARG|gi|686379454|ref|WP_031899389.1|	22.4	210	368	488	4.74e-08	53.5
k141_72403_19	SARG|gi|727749040|ref|WP_033861720.1|	22.4	210	368	488	4.74e-08	53.5
k141_72403_53	SARG|gb|ABA71733.1|ARO:3002972|vanTG	36.9	377	377	712	1.57e-65	219
k141_72403_53	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	34.7	372	377	711	7.52e-56	193
k141_72403_53	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	30.9	372	377	366	5.46e-50	171
k141_72403_53	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	31.5	371	377	712	1.54e-49	176
k141_72403_64	SARG|ZP_02632674	26.2	679	697	660	2.67e-58	207
k141_72403_64	SARG|YP_002850805	26.6	673	697	652	3.23e-58	207
k141_72403_64	SARG|ZP_02952732	26.3	673	697	652	6.10e-58	206
k141_72403_64	SARG|L20800.gene.p01	26.3	673	697	652	6.10e-58	206
k141_72403_64	SARG|NP_348076	25.8	683	697	652	1.46e-56	202
k141_72403_64	SARG|AAV80410	24.8	666	697	651	5.74e-51	187
k141_72403_64	SARG|L42544.gene.p01	24.8	666	697	651	1.46e-50	186
k141_72403_64	SARG|AJ514254.gene.p01	23.1	662	697	640	5.41e-45	169
k141_72403_64	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	23.6	678	697	639	4.27e-42	161
k141_72403_64	SARG|gi|544707441|ref|WP_021137831.1|	23.1	672	697	639	5.77e-42	160
k141_72403_80	megares|MEG_1992|Drugs|beta-lactam|Class_C_betalactamases|CMY_1	34.7	124	302	291	3.66e-11	61.6
k141_72403_82	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.8	724	805	1024	1.93e-17	86.3
k141_72403_82	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.8	724	805	1024	1.93e-17	86.3
k141_72403_82	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.8	724	805	1024	1.93e-17	86.3
k141_72403_82	SARG|gb|CAA53189|ARO:3000521|mupA	22.8	724	805	1024	1.93e-17	86.3
k141_72403_86	SARG|gi|740856590|ref|WP_038641842.1|	41.0	244	262	648	2.08e-43	154
k141_72403_86	SARG|gi|754951242|ref|WP_042307417.1|	41.0	244	262	648	2.86e-43	154
k141_72403_86	SARG|gi|493734654|ref|WP_006683876.1|	41.0	244	262	648	2.86e-43	154
k141_72403_86	SARG|gi|507086196|ref|WP_016156937.1|	40.6	244	262	648	1.43e-42	152
k141_72403_86	SARG|gi|922960663|ref|WP_053388845.1|	40.6	244	262	648	1.97e-42	152
k141_72403_86	SARG|gi|757799695|ref|WP_043016897.1|	40.6	244	262	648	2.71e-42	151
k141_72403_86	SARG|gi|1045891604|ref|WP_065554100.1|	40.6	244	262	648	2.71e-42	151
k141_72403_86	SARG|gi|507082903|ref|WP_016153652.1|	40.6	244	262	648	2.71e-42	151
k141_72403_86	SARG|gi|835233765|ref|WP_047410073.1|	40.6	244	262	648	3.74e-42	151
k141_72403_86	SARG|gi|992380339|ref|WP_061067665.1|	39.8	254	262	648	7.09e-42	150
k141_72403_99	SARG|gb|AAG05187.1|ARO:3005067|ParS	29.2	240	386	428	1.33e-25	106
k141_72403_99	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.8	228	386	361	9.73e-20	88.6
k141_72403_99	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.0	215	386	359	2.99e-17	81.3
k141_72403_99	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.2	255	386	364	8.26e-16	77.0
k141_72403_99	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.2	255	386	364	8.26e-16	77.0
k141_72403_99	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	24.2	236	386	364	2.22e-13	69.7
k141_72403_99	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	24.2	236	386	364	2.22e-13	69.7
k141_72403_100	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	39.4	221	227	231	1.07e-45	150
k141_72403_100	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	37.6	226	227	233	4.50e-45	149
k141_72403_100	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.1	221	227	219	3.40e-41	139
k141_72403_100	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	222	227	219	2.12e-39	134
k141_72403_100	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	227	219	8.41e-39	132
k141_72403_100	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	227	220	8.63e-39	132
k141_72403_100	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	227	220	1.22e-38	132
k141_72403_100	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	33.5	218	227	225	1.96e-38	132
k141_72403_100	SARG|ZP_02848503	35.7	224	227	221	2.49e-38	131
k141_72403_100	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.8	221	227	220	9.59e-38	130
k141_101746_3	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	29.0	248	312	314	4.17e-28	109
k141_101746_3	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	30.2	255	312	323	4.88e-28	109
k141_101746_3	SARG|gi|740152780|ref|WP_037997109.1|	29.2	260	312	322	8.54e-25	100
k141_101746_3	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	31.6	231	312	337	1.39e-23	97.8
k141_101746_3	SARG|gi|552942232|ref|WP_023043160.1|	29.0	255	312	323	4.13e-23	96.3
k141_101746_3	SARG|AY082011.1.gene6.p01	28.6	255	312	323	2.82e-22	94.0
k141_101746_13	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.7	228	232	231	1.63e-57	181
k141_101746_13	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.8	230	232	232	4.35e-55	175
k141_101746_13	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.8	230	232	232	4.35e-55	175
k141_101746_13	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.6	233	232	229	7.24e-53	169
k141_101746_13	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.0	228	232	232	8.95e-52	166
k141_101746_13	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.3	232	232	231	2.46e-51	165
k141_101746_13	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.2	232	232	231	2.46e-51	165
k141_101746_13	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.6	232	232	231	9.82e-51	164
k141_101746_13	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.6	233	232	230	3.81e-50	162
k141_101746_13	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.8	232	232	231	3.93e-50	162
k141_101746_14	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.3	138	413	370	2.02e-08	54.7
k141_101746_14	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.1	133	413	365	7.78e-06	46.6
k141_101746_26	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	52.6	1244	1314	1162	0.0	1183
k141_101746_26	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	50.4	1251	1314	1186	0.0	1117
k141_101746_26	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	50.4	1251	1314	1186	0.0	1117
k141_101746_30	SARG|L42544.gene.p01	28.5	694	706	651	6.69e-75	253
k141_101746_30	SARG|AAV80410	28.5	694	706	651	1.29e-74	252
k141_101746_30	SARG|NP_348076	27.6	684	706	652	2.54e-74	251
k141_101746_30	SARG|YP_002850805	27.6	682	706	652	9.27e-72	244
k141_101746_30	SARG|ZP_02952732	27.1	682	706	652	6.47e-70	239
k141_101746_30	SARG|ZP_02632674	27.1	682	706	660	7.56e-70	239
k141_101746_30	SARG|L20800.gene.p01	27.1	682	706	652	2.38e-69	238
k141_101746_30	SARG|AJ514254.gene.p01	27.1	694	706	640	4.63e-66	229
k141_101746_30	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.1	682	706	639	1.46e-62	219
k141_101746_30	SARG|AAO42740	26.7	682	706	639	1.70e-59	211
k141_101746_31	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	38.6	101	108	639	2.69e-12	60.5
k141_130888_4	SARG|YP_001373621	29.8	215	362	318	8.54e-20	87.8
k141_130888_4	SARG|gi|542061059|gb|ERI11611.1|	29.7	192	362	316	2.12e-19	86.7
k141_130888_4	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.9	223	362	293	1.92e-16	77.8
k141_130888_4	SARG|gb|AAK76137.1|ARO:3000024|patA	28.9	204	362	564	4.05e-14	72.4
k141_130888_4	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	28.2	213	362	505	1.19e-12	67.8
k141_130888_4	SARG|gi|446048013|ref|WP_000125868.1|	24.6	199	362	648	2.48e-12	67.0
k141_130888_4	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	28.5	200	362	504	3.76e-12	66.2
k141_130888_4	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	28.6	192	362	552	2.21e-10	60.8
k141_130888_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.6	208	362	664	1.78e-09	58.2
k141_130888_4	SARG|U82085.gene.p01	26.5	200	362	552	6.50e-08	53.1
k141_130888_19	SARG|gb|AAC75314.1|ARO:3003578|pmrF	29.5	329	325	322	2.96e-36	132
k141_130888_20	SARG|CAB61225	25.8	124	195	161	7.08e-07	46.2
k141_130888_20	SARG|ACP19239	32.4	68	195	161	6.41e-06	43.5
k141_130888_20	megares|MEG_7452|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.4	68	195	161	6.41e-06	43.5
k141_130888_57	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.2	558	656	655	8.71e-119	367
k141_130888_57	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.2	558	656	655	8.71e-119	367
k141_130888_57	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.2	558	656	655	1.23e-118	367
k141_130888_57	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_130888_57	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_130888_57	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_130888_57	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_130888_57	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_130888_57	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_130888_57	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.0	558	656	655	1.34e-117	364
k141_60006_25	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.2	113	120	228	3.11e-17	73.2
k141_60006_25	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.8	117	120	229	4.88e-13	62.0
k141_60006_25	CARD|gb|AAC73788.1|ARO:3003841|kdpE	29.7	118	120	225	3.26e-10	54.3
k141_60006_25	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	29.6	115	120	225	1.19e-09	52.8
k141_60006_35	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.5	230	227	231	6.27e-56	177
k141_60006_35	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.5	221	227	220	7.26e-55	174
k141_60006_35	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	232	227	232	7.34e-55	174
k141_60006_35	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.5	221	227	219	9.97e-55	173
k141_60006_35	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.5	221	227	220	1.03e-54	173
k141_60006_35	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.1	221	227	219	8.01e-54	171
k141_60006_35	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.1	221	227	220	9.37e-53	168
k141_60006_35	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.0	228	227	232	5.35e-52	167
k141_60006_35	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.0	228	227	232	5.35e-52	167
k141_60006_35	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.0	229	227	230	2.02e-51	165
k141_60006_36	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.8	312	492	447	4.48e-34	132
k141_60006_36	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.3	314	492	447	1.15e-33	131
k141_60006_36	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.3	314	492	447	1.15e-33	131
k141_60006_36	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	29.3	314	492	447	1.15e-33	131
k141_60006_36	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	28.3	314	492	454	1.36e-31	125
k141_60006_36	CARD|gb|ABD30512.1|ARO:3000839|arlS	23.2	345	492	451	1.32e-20	93.2
k141_60006_36	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	26.9	260	492	384	1.59e-18	86.3
k141_60006_36	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	26.9	260	492	384	1.59e-18	86.3
k141_60006_36	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.2	234	492	359	1.70e-18	85.9
k141_60006_36	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.2	282	492	382	2.81e-18	85.5
k141_60006_44	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	519	547	655	4.14e-69	233
k141_60006_44	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	5.76e-69	233
k141_60006_44	SARG|gb|AKA86814|ARO:3003746|optrA	28.9	519	547	655	5.76e-69	233
k141_60006_44	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	519	547	655	1.11e-68	232
k141_60006_44	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	1.55e-68	232
k141_60006_44	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	1.55e-68	232
k141_60006_44	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	1.55e-68	232
k141_60006_44	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	1.55e-68	232
k141_60006_44	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	1.55e-68	232
k141_60006_44	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	3.00e-68	231
k141_60006_62	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	38.5	221	247	255	1.22e-43	147
k141_60006_62	SARG|gi|974588181|ref|WP_059178476.1|	39.1	220	247	646	3.35e-43	153
k141_60006_62	SARG|YP_001176128	39.1	220	247	646	3.35e-43	153
k141_60006_62	SARG|gi|757782629|ref|WP_043001213.1|	40.0	220	247	648	4.69e-43	153
k141_60006_62	SARG|gi|992390012|ref|WP_061077002.1|	40.0	220	247	648	4.69e-43	153
k141_60006_62	SARG|gi|763407609|ref|WP_044264203.1|	40.0	220	247	648	4.69e-43	153
k141_60006_62	SARG|gi|754927849|ref|WP_042284850.1|	40.0	220	247	648	6.48e-43	152
k141_60006_62	SARG|gi|817104523|ref|WP_046477871.1|	40.0	220	247	648	8.93e-43	152
k141_60006_62	SARG|gi|764278838|ref|WP_044327089.1|	40.0	220	247	648	8.93e-43	152
k141_60006_62	SARG|gi|968563772|ref|WP_058587854.1|	39.5	220	247	648	1.23e-42	152
k141_60006_89	CARD|gb|ALH22601.1|ARO:3000620|adeL	27.6	272	297	337	9.31e-13	66.6
k141_189971_17	CARD|gb|AAC16242.1|ARO:3005069|rsmA	48.1	54	73	61	1.09e-16	65.9
k141_189971_25	SARG|gi|496018010|ref|WP_008742581.1|	34.4	582	576	623	4.97e-100	315
k141_189971_25	SARG|gi|695887424|ref|WP_032788534.1|	33.3	570	576	605	8.63e-100	314
k141_189971_25	SARG|gi|764446018|ref|WP_044369325.1|	33.3	570	576	605	1.21e-99	313
k141_189971_25	SARG|gi|951183771|ref|WP_057661487.1|	33.5	570	576	603	1.62e-99	313
k141_189971_25	SARG|gi|497748188|ref|WP_010062372.1|	33.2	570	576	605	3.37e-99	312
k141_189971_25	SARG|gi|503923650|ref|WP_014157644.1|	33.6	571	576	601	4.26e-99	312
k141_189971_25	SARG|gi|664180077|ref|WP_030714054.1|	33.2	570	576	605	4.73e-99	312
k141_189971_25	SARG|gi|917203192|ref|WP_051809904.1|	33.8	582	576	620	4.98e-99	312
k141_189971_25	SARG|gi|505389066|ref|WP_015576168.1|	33.5	571	576	601	5.99e-99	311
k141_189971_25	SARG|gi|695891735|ref|WP_032792824.1|	33.3	570	576	603	6.31e-99	311
k141_43454_49	CARD|gb|ABD30512.1|ARO:3000839|arlS	25.1	287	347	451	1.32e-26	108
k141_43454_49	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	26.0	250	347	359	5.01e-21	91.7
k141_43454_49	CARD|gb|AEX49906.1|ARO:3003583|basS	25.1	231	347	477	7.51e-19	86.3
k141_43454_49	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.2	263	347	364	7.78e-16	76.6
k141_43454_49	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.2	263	347	364	7.78e-16	76.6
k141_43454_50	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.5	219	224	228	8.90e-43	143
k141_43454_50	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.6	224	224	231	2.72e-42	142
k141_43454_50	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.9	224	224	232	7.86e-42	140
k141_43454_50	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	224	219	2.44e-40	136
k141_43454_50	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	224	219	3.45e-40	136
k141_43454_50	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	224	220	3.55e-40	136
k141_43454_50	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.2	218	224	220	5.00e-40	135
k141_43454_50	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.2	219	224	219	5.43e-39	133
k141_43454_50	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	218	224	220	4.88e-37	128
k141_43454_50	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.0	230	224	231	5.60e-35	123
k141_190055_38	SARG|gi|671541568|ref|WP_031525212.1|	35.6	222	228	648	4.85e-38	138
k141_190055_38	SARG|gi|445996723|ref|WP_000074578.1|	29.2	219	228	309	2.78e-23	94.4
k141_190055_38	SARG|gi|445996722|ref|WP_000074577.1|	28.8	219	228	309	3.86e-23	94.0
k141_190055_38	SARG|gi|445996729|ref|WP_000074584.1|	28.8	219	228	309	7.45e-23	93.2
k141_190055_38	SARG|gi|1043490477|ref|WP_065382463.1|	28.8	219	228	309	7.45e-23	93.2
k141_190055_38	SARG|gi|445996726|ref|WP_000074581.1|	28.8	219	228	309	7.45e-23	93.2
k141_190055_38	SARG|gi|507054395|ref|WP_016125339.1|	28.8	219	228	309	7.45e-23	93.2
k141_190055_38	SARG|gi|445996724|ref|WP_000074579.1|	28.3	219	228	309	1.03e-22	92.8
k141_190055_38	SARG|gi|895808656|emb|COR83787.1|	28.8	219	228	309	1.03e-22	92.8
k141_190055_38	SARG|gi|884875933|emb|CKG93789.1|	28.3	219	228	309	1.43e-22	92.4
k141_147853_4	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.6	251	262	230	1.87e-40	138
k141_147853_4	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	32.8	250	262	231	2.78e-36	127
k141_147853_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.0	256	262	231	1.53e-35	125
k141_147853_4	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	254	262	231	4.26e-35	124
k141_147853_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.1	259	262	239	5.21e-35	124
k141_147853_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.1	255	262	231	5.99e-35	124
k141_147853_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.9	255	262	229	8.01e-35	124
k141_147853_4	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	254	262	231	1.66e-34	123
k141_147853_4	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.0	254	262	231	2.34e-34	122
k141_147853_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.2	255	262	235	7.18e-34	121
k141_147853_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	45.2	303	306	307	1.27e-86	261
k141_147853_5	SARG|ABB80128	44.2	301	306	306	5.18e-83	251
k141_147853_5	SARG|P42332	43.9	301	306	306	1.47e-82	250
k141_147853_5	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	43.9	301	306	306	1.47e-82	250
k141_147853_5	SARG|gi|510143239|gb|AGN36970.1|	43.9	301	306	313	1.83e-82	250
k141_147853_5	SARG|gi|542061059|gb|ERI11611.1|	43.4	302	306	316	2.01e-82	250
k141_147853_5	SARG|AAD21213	43.5	301	306	306	4.17e-82	249
k141_147853_5	SARG|gi|447195835|ref|WP_001273091.1|	44.5	301	306	306	8.34e-82	248
k141_147853_5	SARG|gi|447195836|ref|WP_001273092.1|	44.2	301	306	306	2.37e-81	247
k141_147853_5	SARG|gi|445996732|ref|WP_000074587.1|	43.5	301	306	309	3.68e-81	247
k141_147853_7	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.4	285	316	380	2.28e-26	106
k141_147853_7	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.4	285	316	380	2.28e-26	106
k141_147853_7	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	278	316	381	1.14e-25	104
k141_147853_7	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	278	316	381	1.14e-25	104
k141_147853_7	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.1	278	316	381	5.20e-24	99.8
k141_147853_7	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	278	316	381	5.20e-24	99.8
k141_147853_7	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	269	316	352	6.98e-24	99.0
k141_147853_7	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.0	278	316	381	7.14e-24	99.4
k141_147853_7	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.0	278	316	381	7.14e-24	99.4
k141_147853_7	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	269	316	376	1.75e-23	98.2
k141_147853_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.2	235	335	255	7.70e-26	102
k141_147853_12	SARG|Q83LR7	32.6	230	335	648	1.03e-23	100
k141_147853_12	SARG|gi|647325472|ref|WP_025760953.1|	32.6	230	335	648	1.03e-23	100
k141_147853_12	SARG|gi|647323678|ref|WP_025760497.1|	32.6	230	335	648	1.03e-23	100
k141_147853_12	SARG|gi|974672242|ref|WP_059256507.1|	32.9	231	335	648	2.53e-23	99.8
k141_147853_12	SARG|gi|974641719|ref|WP_059227752.1|	32.9	231	335	648	2.53e-23	99.8
k141_147853_12	SARG|gi|643601187|ref|WP_025237288.1|	32.9	231	335	648	2.53e-23	99.8
k141_147853_12	SARG|gi|974628291|ref|WP_059215695.1|	32.9	231	335	648	2.53e-23	99.8
k141_147853_12	SARG|gi|446110298|ref|WP_000188153.1|	32.9	231	335	648	2.53e-23	99.8
k141_147853_12	SARG|gi|446110299|ref|WP_000188154.1|	32.9	231	335	648	2.53e-23	99.8
k141_147853_13	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.8	263	331	574	3.41e-17	81.3
k141_147853_13	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.7	222	331	550	1.28e-10	61.2
k141_147853_13	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	23.7	190	331	505	8.93e-08	52.4
k141_147853_13	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	24.7	190	331	504	8.70e-07	49.3
k141_147853_27	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	23.7	236	256	307	1.11e-14	71.2
k141_147853_27	SARG|gb|QHW12375.1|ARO:3005087|msrF	28.3	230	256	486	2.86e-14	70.9
k141_147853_27	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	29.4	204	256	491	5.23e-14	70.1
k141_147853_27	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	26.5	230	256	485	1.27e-13	68.9
k141_147853_27	SARG|QHW12308.1	27.8	230	256	486	5.69e-13	67.0
k141_147853_27	SARG|DAC81085.1	26.4	231	256	486	7.66e-13	66.6
k141_147853_27	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	29.4	194	256	485	1.50e-11	62.8
k141_147853_27	SARG|U82085.gene.p01	27.6	192	256	552	3.88e-11	61.6
k141_26942_11	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	32.8	201	544	373	3.56e-27	112
k141_26942_16	SARG|gi|445996719|ref|WP_000074574.1|	29.6	226	286	309	3.90e-23	95.5
k141_26942_16	SARG|gi|445996723|ref|WP_000074578.1|	29.2	226	286	309	7.46e-23	94.7
k141_26942_16	SARG|gi|445996722|ref|WP_000074577.1|	28.8	226	286	309	1.03e-22	94.4
k141_26942_16	SARG|gi|1043490477|ref|WP_065382463.1|	29.2	226	286	309	1.42e-22	94.0
k141_26942_16	SARG|gi|445996726|ref|WP_000074581.1|	29.2	226	286	309	1.42e-22	94.0
k141_26942_16	SARG|gi|447057509|ref|WP_001134765.1|	28.8	226	286	309	1.42e-22	94.0
k141_26942_16	SARG|gi|507054395|ref|WP_016125339.1|	29.2	226	286	309	1.42e-22	94.0
k141_26942_16	SARG|gi|445996724|ref|WP_000074579.1|	28.8	226	286	309	1.97e-22	93.6
k141_26942_16	SARG|gi|884875933|emb|CKG93789.1|	28.3	226	286	309	2.72e-22	93.2
k141_26942_16	SARG|gi|445996729|ref|WP_000074584.1|	28.8	226	286	309	3.75e-22	92.8
k141_26942_17	SARG|gi|851913025|ref|WP_048215946.1|	37.7	228	282	648	3.10e-31	121
k141_26942_17	SARG|YP_002850060	37.7	228	282	648	3.10e-31	121
k141_26942_17	SARG|gi|489930965|ref|WP_003834285.1|	37.7	228	282	648	3.10e-31	121
k141_26942_17	SARG|gi|696368937|ref|WP_032943949.1|	37.9	227	282	648	4.22e-31	120
k141_26942_17	SARG|gi|693054987|ref|WP_032223114.1|	40.1	207	282	648	4.22e-31	120
k141_26942_17	SARG|gi|489936909|ref|WP_003840216.1|	37.7	228	282	648	4.22e-31	120
k141_26942_17	SARG|gi|507079862|ref|WP_016150620.1|	37.7	228	282	648	4.22e-31	120
k141_26942_17	SARG|gi|949791377|ref|WP_057104572.1|	37.7	228	282	648	4.22e-31	120
k141_26942_17	SARG|gi|696361545|ref|WP_032936694.1|	37.9	227	282	648	5.75e-31	120
k141_26942_17	SARG|gi|851922185|ref|WP_048218206.1|	37.7	228	282	648	7.83e-31	120
k141_39819_14	SARG|gi|922960663|ref|WP_053388845.1|	35.7	224	227	648	1.81e-38	139
k141_39819_14	SARG|gi|757799695|ref|WP_043016897.1|	35.7	224	227	648	2.49e-38	139
k141_39819_14	SARG|gi|1045891604|ref|WP_065554100.1|	35.7	224	227	648	2.49e-38	139
k141_39819_14	SARG|gi|507082903|ref|WP_016153652.1|	35.7	224	227	648	2.49e-38	139
k141_39819_14	SARG|gi|740856590|ref|WP_038641842.1|	35.7	224	227	648	3.42e-38	139
k141_39819_14	SARG|gi|507086196|ref|WP_016156937.1|	35.7	224	227	648	4.70e-38	138
k141_39819_14	SARG|gi|835233765|ref|WP_047410073.1|	35.7	224	227	648	6.45e-38	138
k141_39819_14	SARG|gi|754951242|ref|WP_042307417.1|	35.7	224	227	648	8.86e-38	137
k141_39819_14	SARG|gi|493734654|ref|WP_006683876.1|	35.7	224	227	648	8.86e-38	137
k141_39819_14	SARG|gi|491270241|ref|WP_005128370.1|	35.6	222	227	648	1.67e-37	137
k141_39819_15	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.9	226	230	231	9.03e-62	192
k141_39819_15	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.3	227	230	232	1.71e-59	186
k141_39819_15	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.4	228	230	229	3.14e-59	185
k141_39819_15	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.4	227	230	232	6.89e-59	184
k141_39819_15	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.4	227	230	232	6.89e-59	184
k141_39819_15	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	39.5	233	230	239	3.41e-58	183
k141_39819_15	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.3	231	230	235	8.58e-58	182
k141_39819_15	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.0	227	230	231	6.12e-57	179
k141_39819_15	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.0	227	230	231	6.12e-57	179
k141_39819_15	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.5	227	230	231	4.91e-56	177
k141_39819_16	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	30.9	262	808	357	2.51e-31	125
k141_39819_16	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	30.9	262	808	357	2.51e-31	125
k141_39819_16	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.4	306	808	370	4.32e-31	124
k141_39819_16	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	31.0	303	808	365	7.20e-31	124
k141_39819_16	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.9	242	808	381	3.04e-23	101
k141_39819_16	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.9	242	808	381	3.04e-23	101
k141_39819_16	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.5	242	808	381	4.08e-23	101
k141_39819_16	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.9	242	808	381	4.08e-23	101
k141_39819_16	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.5	242	808	381	4.08e-23	101
k141_39819_16	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.9	242	808	381	4.08e-23	101
k141_39819_22	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.7	219	223	228	2.40e-48	157
k141_39819_22	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.2	229	223	231	6.64e-46	151
k141_39819_22	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.2	229	223	231	6.64e-46	151
k141_39819_22	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.7	229	223	231	2.10e-44	147
k141_39819_22	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.9	232	223	230	9.10e-43	143
k141_39819_22	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.6	226	223	232	2.71e-42	142
k141_39819_22	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.9	229	223	231	1.83e-39	134
k141_39819_22	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.2	226	223	231	1.02e-38	132
k141_39819_22	CARD|gb|AAD51348.1|ARO:3003066|smeR	37.4	222	223	229	3.83e-38	131
k141_39819_22	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.9	231	223	229	3.83e-38	131
k141_39819_23	CARD|gb|ABD30512.1|ARO:3000839|arlS	26.9	297	441	451	1.80e-29	118
k141_39819_23	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.5	216	441	381	3.14e-28	114
k141_39819_23	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.5	216	441	381	3.14e-28	114
k141_39819_23	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.0	216	441	381	8.05e-28	112
k141_39819_23	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.0	216	441	381	8.05e-28	112
k141_39819_23	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.1	327	441	392	8.31e-27	110
k141_39819_23	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.8	254	441	370	4.17e-24	102
k141_39819_23	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.2	265	441	365	2.48e-23	99.8
k141_39819_23	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	22.8	438	441	447	7.70e-17	81.3
k141_39819_25	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	54.1	532	688	655	5.46e-202	582
k141_39819_25	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.9	532	688	655	4.39e-201	580
k141_39819_25	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.9	532	688	655	4.39e-201	580
k141_39819_25	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.9	532	688	655	8.79e-201	579
k141_39819_25	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.8	532	688	655	7.07e-200	577
k141_39819_25	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.8	532	688	655	7.07e-200	577
k141_39819_25	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.8	532	688	655	7.07e-200	577
k141_39819_25	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.8	532	688	655	7.07e-200	577
k141_39819_25	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.8	532	688	655	7.07e-200	577
k141_39819_25	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	53.8	532	688	655	7.07e-200	577
k141_39819_28	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	30.1	365	352	366	4.13e-43	152
k141_39819_29	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.3	459	465	451	2.51e-91	283
k141_39819_29	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	37.7	459	465	481	4.18e-91	284
k141_39819_29	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	37.4	457	465	451	9.92e-91	282
k141_197995_21	SARG|ZP_04081918	35.8	313	315	306	6.61e-50	167
k141_197995_21	SARG|gi|500194536|ref|WP_011867743.1|	34.7	314	315	306	1.10e-47	161
k141_197995_21	SARG|gi|447195835|ref|WP_001273091.1|	39.7	247	315	306	1.10e-47	161
k141_197995_21	SARG|YP_001373621	38.8	232	315	318	2.10e-47	160
k141_197995_21	SARG|P42332	34.2	313	315	306	3.07e-47	160
k141_197995_21	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	34.2	313	315	306	3.07e-47	160
k141_197995_21	SARG|gi|447195836|ref|WP_001273092.1|	39.3	247	315	306	3.07e-47	160
k141_197995_21	SARG|gi|510143239|gb|AGN36970.1|	34.2	313	315	313	3.67e-47	160
k141_197995_21	SARG|gi|542061059|gb|ERI11611.1|	34.8	313	315	316	3.95e-47	160
k141_197995_21	SARG|ABB80128	34.2	313	315	306	4.32e-47	159
k141_197995_35	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	40.1	689	641	703	1.64e-142	430
k141_197995_44	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.6	225	302	343	1.49e-29	114
k141_197995_44	SARG|YP_001373621	32.1	224	302	318	3.60e-28	109
k141_197995_44	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	30.3	238	302	307	2.96e-27	107
k141_48336_22	SARG|gb|WP_104671188.1|ARO:3003948|efrA	24.5	216	259	575	1.80e-14	71.6
k141_48336_22	SARG|AXF35727.1	25.6	203	259	497	2.29e-10	59.3
k141_48336_22	SARG|gi|727118387|ref|WP_033626720.1|	27.9	197	259	498	1.00e-09	57.4
k141_48336_22	SARG|gi|488349878|ref|WP_002419263.1|	27.9	197	259	498	1.00e-09	57.4
k141_48336_22	SARG|gi|498528849|ref|WP_010828356.1|	27.9	197	259	498	1.34e-09	57.0
k141_48336_22	SARG|gi|881017353|ref|WP_048737885.1|	27.9	197	259	498	1.80e-09	56.6
k141_48336_22	SARG|gi|514883218|ref|WP_016615053.1|	27.9	197	259	498	1.80e-09	56.6
k141_48336_22	SARG|gi|488303094|ref|WP_002374069.1|	27.9	197	259	498	1.80e-09	56.6
k141_48336_22	SARG|gi|488319039|ref|WP_002388424.1|	27.9	197	259	498	1.80e-09	56.6
k141_48336_22	SARG|gi|498397181|ref|WP_010710665.1|	27.9	197	259	498	1.80e-09	56.6
k141_98360_19	CARD|gb|AAG06465.1|ARO:3005063|cprR	38.2	76	238	223	1.18e-08	52.8
k141_98360_19	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	24.4	172	238	225	5.55e-08	50.8
k141_98360_19	CARD|gb|ATC67679.1|ARO:3000838|arlR	29.3	82	238	219	4.98e-06	45.1
k141_98360_19	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.3	132	238	220	5.02e-06	45.1
k141_98360_19	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.3	132	238	219	6.73e-06	44.7
k141_98360_19	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.3	132	238	219	6.73e-06	44.7
k141_98360_19	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.3	132	238	220	6.78e-06	44.7
k141_60754_27	SARG|gb|CAH14033.1|ARO:3004100|LpeB	25.0	835	1256	1014	1.93e-51	196
k141_60754_27	CARD|gb|AAG07594.1|ARO:3000808|MexI	23.1	856	1256	1029	1.14e-43	172
k141_60754_27	CARD|gb|ABS43151.1|ARO:3000784|cmeB	22.3	866	1256	1040	5.17e-41	163
k141_60754_27	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	22.7	803	1256	1039	2.70e-40	161
k141_60754_27	SARG|gi|654933144|ref|WP_028383500.1|	23.9	798	1256	1063	3.73e-40	160
k141_60754_27	SARG|gi|780147796|ref|WP_045491627.1|	24.2	790	1256	1063	4.45e-39	157
k141_60754_27	SARG|gi|504104202|ref|WP_014338188.1|	23.9	787	1256	1059	1.75e-38	155
k141_60754_27	SARG|YP_607927	23.4	803	1256	1059	2.30e-38	155
k141_60754_27	SARG|CAY49157	23.7	793	1256	1059	2.30e-38	155
k141_60754_27	SARG|gi|491017944|ref|WP_004879650.1|	24.1	790	1256	1063	2.32e-38	155
k141_60754_32	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.1	804	883	1024	3.10e-68	244
k141_60754_32	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.1	804	883	1024	3.10e-68	244
k141_60754_32	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.1	804	883	1024	5.71e-68	244
k141_60754_32	SARG|gb|CAA53189|ARO:3000521|mupA	24.1	804	883	1024	5.71e-68	244
k141_52535_12	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	29.0	480	452	533	1.23e-39	148
k141_32287_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.8	332	516	370	5.13e-32	125
k141_32287_2	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.6	340	516	365	1.02e-27	113
k141_32287_2	CARD|gb|AAD51347.1|ARO:3003067|smeS	24.7	344	516	467	3.92e-21	95.1
k141_32287_2	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.5	277	516	359	8.26e-18	84.0
k141_32287_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.8	324	516	381	4.45e-16	79.0
k141_32287_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.8	324	516	381	4.45e-16	79.0
k141_32287_2	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	22.5	276	516	388	6.24e-16	78.6
k141_32287_2	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	22.5	276	516	388	6.24e-16	78.6
k141_32287_2	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	22.7	277	516	384	1.08e-15	77.8
k141_32287_2	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	22.7	277	516	384	1.08e-15	77.8
k141_32287_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.8	225	224	231	5.85e-53	169
k141_32287_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.1	225	224	232	1.25e-46	153
k141_32287_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.6	217	224	219	7.77e-45	148
k141_32287_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.4	229	224	233	2.29e-44	147
k141_32287_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.1	232	224	235	3.03e-42	142
k141_32287_3	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.2	222	224	223	6.15e-42	140
k141_32287_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.4	229	224	229	4.06e-41	139
k141_32287_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.3	217	224	219	6.16e-41	138
k141_32287_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.3	217	224	219	8.69e-41	137
k141_32287_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.3	217	224	220	8.93e-41	137
k141_140026_12	SARG|gb|AAK76136.1|ARO:3000025|patB	34.4	552	585	588	1.19e-105	329
k141_140026_12	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.8	500	585	664	4.35e-101	319
k141_140026_12	SARG|gb|CDO61516.1|ARO:3003949|efrB	46.4	323	585	362	3.00e-90	281
k141_140026_12	SARG|gi|496018010|ref|WP_008742581.1|	31.5	540	585	623	1.29e-83	272
k141_140026_12	SARG|gi|860594225|ref|WP_048475168.1|	31.0	542	585	620	1.69e-83	272
k141_140026_12	SARG|gi|917203192|ref|WP_051809904.1|	32.1	546	585	620	3.30e-83	271
k141_140026_12	SARG|gi|926294973|ref|WP_053631154.1|	31.7	546	585	620	9.05e-83	270
k141_140026_12	SARG|gi|917172177|ref|WP_051778889.1|	34.3	493	585	620	1.27e-82	270
k141_140026_12	SARG|gi|926356413|ref|WP_053687351.1|	31.7	546	585	620	1.27e-82	270
k141_140026_12	SARG|gi|917166849|ref|WP_051773561.1|	34.1	493	585	620	1.27e-82	270
k141_140026_13	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.6	578	583	575	4.50e-122	371
k141_140026_13	SARG|gb|AAK76137.1|ARO:3000024|patA	32.3	573	583	564	4.81e-87	280
k141_140026_13	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.6	579	583	579	1.57e-58	204
k141_140026_13	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.5	541	583	574	1.94e-57	201
k141_140026_13	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.7	580	583	579	7.81e-57	199
k141_140026_13	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	27.3	575	583	579	2.77e-55	195
k141_140026_13	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	27.2	578	583	579	3.84e-55	195
k141_140026_13	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.4	538	583	664	1.87e-53	192
k141_140026_13	SARG|gi|655413091|ref|WP_028811890.1|	38.4	289	583	603	5.23e-53	189
k141_140026_13	SARG|gb|AAK76136.1|ARO:3000025|patB	28.3	530	583	588	5.67e-53	189
k141_140026_25	CARD|gb|WKR28567.1|ARO:3007678|IreK	31.8	647	720	718	2.55e-80	270
k141_140026_27	SARG|AXY65402.1	33.6	348	355	357	4.82e-50	170
k141_140026_30	SARG|gi|489117806|ref|WP_003027650.1|	30.4	316	311	660	4.62e-47	166
k141_140026_30	SARG|gi|507086291|ref|WP_016157032.1|	30.7	316	311	660	6.38e-47	166
k141_140026_30	SARG|gi|696375142|ref|WP_032949690.1|	30.4	316	311	660	6.38e-47	166
k141_140026_30	SARG|gi|765458296|ref|WP_044714032.1|	30.4	316	311	660	8.80e-47	166
k141_140026_30	SARG|gi|489931383|ref|WP_003834702.1|	30.4	316	311	660	1.22e-46	165
k141_140026_30	SARG|gi|851965596|ref|WP_048234849.1|	30.1	316	311	660	4.41e-46	164
k141_140026_30	SARG|gi|507083067|ref|WP_016153816.1|	30.4	316	311	660	6.09e-46	163
k141_140026_30	SARG|gi|507079934|ref|WP_016150692.1|	30.1	316	311	660	8.40e-46	163
k141_140026_30	SARG|gi|851917461|ref|WP_048217311.1|	30.1	316	311	660	8.40e-46	163
k141_140026_30	SARG|gi|851981245|ref|WP_048240645.1|	30.1	316	311	660	8.40e-46	163
k141_140026_75	SARG|gb|AAV85982.1|ARO:3000535|macB	34.1	428	420	644	1.70e-50	179
k141_140026_75	SARG|gi|1035670474|ref|WP_064517458.1|	32.2	426	420	648	9.74e-42	155
k141_140026_75	SARG|gi|1035717981|ref|WP_064557480.1|	32.2	426	420	648	9.74e-42	155
k141_140026_75	SARG|gi|657888313|ref|WP_029592374.1|	31.2	423	420	648	2.51e-41	154
k141_140026_75	SARG|gi|639218559|ref|WP_024556062.1|	31.2	423	420	648	3.43e-41	153
k141_140026_75	SARG|gi|495067432|ref|WP_007792257.1|	30.6	421	420	647	1.20e-40	152
k141_140026_75	SARG|gi|736472622|ref|WP_034494292.1|	31.9	426	420	648	1.21e-40	152
k141_140026_75	SARG|gi|696411918|ref|WP_032982657.1|	30.6	421	420	647	2.24e-40	151
k141_140026_75	SARG|gi|696402390|ref|WP_032974230.1|	30.6	421	420	647	2.24e-40	151
k141_140026_75	SARG|gi|565651791|ref|WP_023899061.1|	30.6	421	420	647	2.24e-40	151
k141_140026_77	SARG|gi|851922185|ref|WP_048218206.1|	53.7	218	235	648	4.55e-75	238
k141_140026_77	SARG|gi|949718947|ref|WP_057063453.1|	53.7	218	235	648	4.55e-75	238
k141_140026_77	SARG|gi|696375069|ref|WP_032949617.1|	53.7	218	235	648	4.55e-75	238
k141_140026_77	SARG|gi|489127020|ref|WP_003036815.1|	53.7	218	235	648	4.55e-75	238
k141_140026_77	SARG|gi|696368937|ref|WP_032943949.1|	53.7	218	235	648	8.96e-75	237
k141_140026_77	SARG|gi|851913025|ref|WP_048215946.1|	53.7	218	235	648	8.96e-75	237
k141_140026_77	SARG|gi|489930965|ref|WP_003834285.1|	53.7	218	235	648	8.96e-75	237
k141_140026_77	SARG|gi|696361545|ref|WP_032936694.1|	53.7	218	235	648	1.26e-74	237
k141_140026_77	SARG|gi|489936909|ref|WP_003840216.1|	53.7	218	235	648	1.26e-74	237
k141_140026_77	SARG|gi|507079862|ref|WP_016150620.1|	53.7	218	235	648	1.26e-74	237
k141_140026_92	SARG|gb|AAK76137.1|ARO:3000024|patA	34.5	566	583	564	3.51e-100	314
k141_140026_92	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.5	548	583	575	4.74e-100	314
k141_140026_92	SARG|gb|AAK76136.1|ARO:3000025|patB	28.1	519	583	588	1.40e-62	215
k141_140026_92	SARG|gi|1045390184|ref|WP_065479071.1|	29.0	534	583	605	2.61e-60	209
k141_140026_92	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.7	465	583	664	5.15e-60	210
k141_140026_92	SARG|gi|497748188|ref|WP_010062372.1|	28.8	534	583	605	2.56e-59	207
k141_140026_92	SARG|gi|764446018|ref|WP_044369325.1|	28.8	534	583	605	9.43e-59	205
k141_140026_92	SARG|gi|501350226|ref|WP_012381861.1|	28.5	534	583	603	1.74e-58	204
k141_140026_92	SARG|gi|695865802|ref|WP_032778631.1|	28.7	534	583	605	1.81e-58	204
k141_140026_92	SARG|gi|664180077|ref|WP_030714054.1|	28.7	534	583	605	2.50e-58	204
k141_140026_93	SARG|gb|AAK76136.1|ARO:3000025|patB	31.5	604	631	588	1.24e-95	304
k141_140026_93	SARG|gb|AYV52072.1|ARO:3002882|lmrD	31.4	592	631	664	4.00e-90	292
k141_140026_93	SARG|gi|944009777|ref|WP_055601444.1|	31.5	622	631	628	1.97e-79	263
k141_140026_93	SARG|gi|497748188|ref|WP_010062372.1|	30.0	607	631	605	1.69e-78	259
k141_140026_93	SARG|gi|695887424|ref|WP_032788534.1|	29.8	604	631	605	3.29e-78	259
k141_140026_93	SARG|gi|951183771|ref|WP_057661487.1|	30.1	607	631	603	8.55e-78	258
k141_140026_93	SARG|gi|827013130|ref|WP_047175495.1|	30.5	607	631	603	1.19e-77	257
k141_140026_93	SARG|gi|764446018|ref|WP_044369325.1|	29.7	607	631	605	1.25e-77	257
k141_140026_93	SARG|gi|664180077|ref|WP_030714054.1|	29.6	604	631	605	1.25e-77	257
k141_140026_93	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	30.3	597	631	578	1.82e-77	256
k141_140026_149	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	39.6	503	522	533	3.29e-105	324
k141_140026_149	SARG|AF353562.gene.p01	36.8	345	522	369	6.38e-63	209
k141_140026_174	SARG|CAA37477	47.1	140	611	663	6.81e-29	120
k141_140026_174	SARG|NP_348076	45.1	142	611	652	1.16e-27	117
k141_140026_174	SARG|ZP_02952732	44.4	142	611	652	4.85e-27	115
k141_140026_174	SARG|L20800.gene.p01	44.4	142	611	652	4.85e-27	115
k141_140026_174	SARG|ZP_02632674	44.4	142	611	660	4.98e-27	115
k141_140026_174	SARG|YP_002850805	43.0	142	611	652	6.46e-27	114
k141_140026_174	SARG|ABN79417	41.5	142	611	639	4.48e-25	108
k141_140026_174	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	41.5	142	611	629	7.68e-25	108
k141_140026_174	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	41.5	142	611	629	7.68e-25	108
k141_140026_174	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	41.5	142	611	629	7.68e-25	108
k141_186569_32	SARG|L42544.gene.p01	31.6	678	940	651	1.89e-83	281
k141_186569_32	SARG|AAV80410	31.3	678	940	651	4.85e-82	277
k141_186569_32	SARG|YP_002850805	31.9	668	940	652	4.44e-79	269
k141_186569_32	SARG|ZP_02952732	32.1	664	940	652	5.87e-78	266
k141_186569_32	SARG|L20800.gene.p01	32.1	664	940	652	5.87e-78	266
k141_186569_32	SARG|ZP_02632674	32.1	664	940	660	6.98e-78	266
k141_186569_32	SARG|NP_348076	30.7	671	940	652	1.54e-77	265
k141_186569_32	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.0	656	940	641	9.13e-73	251
k141_186569_32	SARG|AAZ79478	29.0	656	940	657	1.27e-72	251
k141_186569_32	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	29.1	656	940	654	3.11e-72	250
k141_149097_5	SARG|gi|754724054|ref|WP_042095806.1|	39.6	230	239	648	8.74e-53	179
k141_149097_5	SARG|gi|693238509|ref|WP_032348033.1|	39.6	230	239	648	8.74e-53	179
k141_149097_5	SARG|gi|485870849|ref|WP_001467831.1|	39.6	230	239	648	8.74e-53	179
k141_149097_5	SARG|gi|979505419|ref|WP_059334195.1|	39.6	230	239	648	1.22e-52	179
k141_149097_5	SARG|ZP_04001960	39.6	230	239	648	1.22e-52	179
k141_149097_5	SARG|gi|545164255|ref|WP_021518974.1|	39.6	230	239	648	1.22e-52	179
k141_149097_5	SARG|gi|979422229|ref|WP_059319814.1|	39.6	230	239	648	1.22e-52	179
k141_149097_5	SARG|gi|1001782895|ref|WP_061321573.1|	39.6	230	239	648	1.22e-52	179
k141_149097_5	SARG|gi|754731641|ref|WP_042100724.1|	39.6	230	239	648	1.22e-52	179
k141_149097_5	SARG|gi|754637749|ref|WP_042024023.1|	39.6	230	239	648	1.22e-52	179
k141_149097_11	SARG|DQ212986.1.gene3.p01	64.3	42	45	75	1.10e-13	57.4
k141_187214_33	SARG|gb|APB03219.1|ARO:3003986|TaeA	48.7	657	625	648	1.69e-203	583
k141_187214_33	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	536	625	655	4.78e-68	233
k141_187214_33	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	536	625	655	6.63e-68	232
k141_187214_33	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	3.41e-67	230
k141_187214_33	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	6.56e-67	229
k141_187214_33	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	6.56e-67	229
k141_187214_33	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	6.56e-67	229
k141_187214_33	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	6.56e-67	229
k141_187214_33	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	9.10e-67	229
k141_187214_33	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.8	536	625	655	9.10e-67	229
k141_187214_42	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	43.7	1042	1056	1024	9.04e-319	908
k141_187214_42	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.7	1042	1056	1024	9.04e-319	908
k141_187214_42	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	43.4	1042	1056	1024	6.56e-316	901
k141_187214_42	SARG|gb|CAA53189|ARO:3000521|mupA	43.4	1042	1056	1024	6.56e-316	901
k141_187214_42	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	44.3	1006	1056	1033	8.87e-316	901
k141_187214_42	SARG|gb|AEY83581|ARO:3000510|mupB	44.3	1006	1056	1033	8.87e-316	901
k141_187214_42	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	36.2	1116	1056	1107	1.40e-217	651
k141_187214_42	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	36.2	1116	1056	1107	1.40e-217	651
k141_187214_48	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.7	107	532	229	2.52e-10	59.7
k141_187214_48	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.8	159	532	219	1.96e-08	53.9
k141_187214_48	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.7	119	532	228	1.29e-07	51.6
k141_187214_48	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.8	124	532	204	1.31e-07	51.2
k141_187214_48	CARD|gb|ADM92605.1|ARO:3000553|adeR	25.6	133	532	247	3.87e-06	47.4
k141_187214_51	CARD|gb|AFK13828.1|ARO:3000823|ramA	30.9	97	286	124	5.37e-12	60.8
k141_129153_6	SARG|gi|507044560|ref|WP_016115614.1|	28.1	199	242	306	1.36e-21	90.1
k141_129153_6	SARG|gi|500448961|gb|EOP61695.1|	30.0	203	242	306	3.62e-21	89.0
k141_129153_6	SARG|gi|500465078|gb|EOP76697.1|	30.0	203	242	306	5.01e-21	88.6
k141_129153_6	SARG|gi|446026113|ref|WP_000103968.1|	27.6	199	242	306	1.32e-20	87.4
k141_129153_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.7	230	242	307	1.34e-20	87.4
k141_129153_6	SARG|P42332	29.0	224	242	306	1.83e-20	87.0
k141_129153_6	SARG|ABB80128	29.0	224	242	306	1.83e-20	87.0
k141_129153_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.0	224	242	306	1.83e-20	87.0
k141_129153_6	SARG|gi|510143239|gb|AGN36970.1|	29.0	224	242	313	2.00e-20	87.0
k141_129153_6	SARG|gi|445996710|ref|WP_000074565.1|	29.6	203	242	309	2.63e-20	86.7
k141_129153_26	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.0	104	337	204	1.02e-06	47.8
k141_129153_47	SARG|gi|445996710|ref|WP_000074565.1|	39.2	209	216	309	2.38e-47	157
k141_129153_47	SARG|gi|447195835|ref|WP_001273091.1|	40.5	210	216	306	8.72e-47	155
k141_129153_47	SARG|gi|445996719|ref|WP_000074574.1|	38.8	209	216	309	1.87e-46	154
k141_129153_47	SARG|ZP_04081918	40.0	210	216	306	2.44e-46	154
k141_129153_47	SARG|gi|447195836|ref|WP_001273092.1|	40.0	210	216	306	2.44e-46	154
k141_129153_47	SARG|gi|445996722|ref|WP_000074577.1|	39.2	209	216	309	3.71e-46	154
k141_129153_47	SARG|gi|445996723|ref|WP_000074578.1|	38.8	209	216	309	5.23e-46	153
k141_129153_47	SARG|gi|488042066|ref|WP_002113463.1|	38.3	209	216	309	7.37e-46	153
k141_129153_47	SARG|gi|895808656|emb|COR83787.1|	38.3	209	216	309	7.37e-46	153
k141_129153_47	SARG|gi|445996724|ref|WP_000074579.1|	38.8	209	216	309	1.04e-45	152
k141_129153_48	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	42.9	56	61	307	1.31e-08	47.8
k141_129153_52	SARG|gi|500194536|ref|WP_011867743.1|	39.9	208	209	306	1.04e-38	134
k141_129153_52	SARG|gi|500465078|gb|EOP76697.1|	41.7	192	209	306	4.06e-38	132
k141_129153_52	SARG|gi|500448961|gb|EOP61695.1|	41.7	192	209	306	5.71e-38	132
k141_129153_52	SARG|gi|445996719|ref|WP_000074574.1|	40.1	207	209	309	8.57e-38	132
k141_129153_52	SARG|gi|445996729|ref|WP_000074584.1|	40.1	207	209	309	2.38e-37	130
k141_129153_52	SARG|gi|507050365|ref|WP_016121371.1|	39.6	207	209	309	2.38e-37	130
k141_129153_52	SARG|gi|542061059|gb|ERI11611.1|	38.0	208	209	316	2.77e-37	130
k141_129153_52	SARG|gi|447195835|ref|WP_001273091.1|	40.9	193	209	306	3.13e-37	130
k141_129153_52	SARG|gi|507044560|ref|WP_016115614.1|	40.6	192	209	306	3.13e-37	130
k141_129153_52	SARG|gi|445996710|ref|WP_000074565.1|	40.9	193	209	309	3.34e-37	130
k141_129153_70	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	26.3	205	246	343	1.36e-15	73.9
k141_129153_74	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.4	609	610	579	4.29e-90	289
k141_129153_74	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.6	605	610	574	1.57e-82	269
k141_129153_74	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.4	557	610	582	1.58e-66	226
k141_129153_74	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.6	516	610	664	1.95e-63	220
k141_129153_74	SARG|gi|1045390184|ref|WP_065479071.1|	30.4	593	610	605	2.48e-63	218
k141_129153_74	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.6	606	610	575	2.65e-63	218
k141_129153_74	SARG|gi|928900436|ref|WP_053931243.1|	30.5	593	610	600	6.01e-63	217
k141_129153_74	SARG|gi|664579989|ref|WP_031094015.1|	30.5	593	610	601	6.13e-63	217
k141_129153_74	SARG|gb|AAK76137.1|ARO:3000024|patA	26.4	591	610	564	4.07e-62	214
k141_129153_74	SARG|gb|AAK76136.1|ARO:3000025|patB	27.1	612	610	588	6.54e-62	214
k141_129153_75	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.1	578	587	579	7.54e-97	306
k141_129153_75	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	35.2	577	587	579	2.94e-96	304
k141_129153_75	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	33.6	581	587	578	2.56e-93	296
k141_129153_75	SARG|gb|AAK76136.1|ARO:3000025|patB	30.9	579	587	588	2.22e-89	286
k141_129153_75	SARG|gi|1045390184|ref|WP_065479071.1|	31.2	567	587	605	9.96e-88	283
k141_129153_75	SARG|gi|695865802|ref|WP_032778631.1|	31.1	566	587	605	7.54e-87	280
k141_129153_75	SARG|gi|764446018|ref|WP_044369325.1|	30.9	566	587	605	1.06e-86	280
k141_129153_75	SARG|gi|664180077|ref|WP_030714054.1|	31.1	566	587	605	1.48e-86	280
k141_129153_75	SARG|gi|517381192|ref|WP_018555350.1|	31.4	566	587	602	3.79e-86	278
k141_129153_75	SARG|gi|497748188|ref|WP_010062372.1|	31.1	566	587	605	4.07e-86	278
k141_53623_6	SARG|gi|1035706844|ref|WP_064548272.1|	30.0	237	265	648	6.98e-20	87.8
k141_53623_6	SARG|gi|803568669|ref|WP_046077412.1|	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|gi|446110352|ref|WP_000188207.1|	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|YP_002382193	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|gi|803575554|ref|WP_046081557.1|	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|gi|1035670474|ref|WP_064517458.1|	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|gi|446110351|ref|WP_000188206.1|	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|gi|1035717981|ref|WP_064557480.1|	29.1	237	265	648	9.44e-20	87.4
k141_53623_6	SARG|gi|736472622|ref|WP_034494292.1|	29.1	237	265	648	1.73e-19	86.7
k141_53623_6	SARG|gi|502669352|ref|WP_012905216.1|	27.8	237	265	648	1.06e-18	84.3
k141_53623_14	SARG|gi|542061059|gb|ERI11611.1|	25.9	239	500	316	3.10e-16	78.6
k141_53623_14	SARG|ZP_04081918	27.0	226	500	306	1.22e-15	76.6
k141_53623_14	SARG|gi|500194536|ref|WP_011867743.1|	27.6	232	500	306	2.21e-15	75.9
k141_53623_14	SARG|P42332	27.6	225	500	306	7.22e-15	74.3
k141_53623_14	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.6	225	500	306	7.22e-15	74.3
k141_53623_14	SARG|gi|510143239|gb|AGN36970.1|	27.6	225	500	313	7.77e-15	74.3
k141_53623_14	SARG|ABB80128	27.7	220	500	306	9.70e-15	73.9
k141_53623_14	SARG|gi|447195835|ref|WP_001273091.1|	27.5	218	500	306	9.70e-15	73.9
k141_53623_14	SARG|gi|447195836|ref|WP_001273092.1|	27.5	218	500	306	9.70e-15	73.9
k141_53623_14	SARG|gi|500448961|gb|EOP61695.1|	25.3	225	500	306	2.35e-14	72.8
k141_53633_14	SARG|gb|APB03216.1|ARO:3003982|LlmA	59.9	294	297	287	3.53e-131	373
k141_53633_61	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.2	224	230	231	1.58e-62	194
k141_53633_61	CARD|gb|ATC67679.1|ARO:3000838|arlR	44.4	225	230	219	3.55e-61	190
k141_53633_61	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.3	230	230	232	7.50e-61	189
k141_53633_61	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.3	230	230	232	7.50e-61	189
k141_53633_61	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.2	224	230	231	4.14e-60	187
k141_53633_61	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.8	225	230	233	4.40e-60	187
k141_53633_61	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.4	225	230	232	1.71e-59	186
k141_53633_61	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.8	224	230	231	2.35e-59	186
k141_53633_61	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.8	224	230	231	3.33e-59	185
k141_53633_61	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.2	224	230	231	1.34e-58	184
k141_53633_62	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.5	308	500	354	5.44e-28	113
k141_53633_62	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.8	266	500	354	1.38e-27	112
k141_53633_62	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.6	258	500	352	3.39e-27	111
k141_53633_62	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.6	258	500	376	4.88e-27	111
k141_53633_62	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	30.6	258	500	376	4.88e-27	111
k141_53633_62	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	29.5	244	500	364	1.21e-25	107
k141_53633_62	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	29.5	244	500	364	1.21e-25	107
k141_53633_62	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	30.5	226	500	359	1.77e-24	103
k141_53633_62	SARG|gb|AAG05187.1|ARO:3005067|ParS	24.2	297	500	428	1.19e-20	93.2
k141_53633_62	CARD|gb|AEX49906.1|ARO:3003583|basS	27.2	261	500	477	2.92e-19	89.4
k141_53633_63	NCBI|EFF39147.1|1|1|norM-NG|norM-NG|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_NorM|AMR|efflux	20.7	363	462	459	3.73e-13	70.1
k141_53633_63	SARG|NC_011035.1.6448920.p01	20.7	363	462	459	3.73e-13	70.1
k141_53633_63	SARG|gi|488158065|ref|WP_002229273.1|	20.7	363	462	459	4.96e-13	69.7
k141_53633_63	SARG|gi|488156254|ref|WP_002227462.1|	20.5	370	462	459	1.55e-12	68.2
k141_53633_70	SARG|gi|895736250|emb|COF64653.1|	30.4	260	294	309	1.82e-25	102
k141_53633_70	SARG|gi|1043490477|ref|WP_065382463.1|	30.8	260	294	309	2.53e-25	101
k141_53633_70	SARG|gi|445996726|ref|WP_000074581.1|	30.8	260	294	309	2.53e-25	101
k141_53633_70	SARG|gi|445996723|ref|WP_000074578.1|	30.8	260	294	309	2.53e-25	101
k141_53633_70	SARG|gi|895808656|emb|COR83787.1|	30.4	260	294	309	2.53e-25	101
k141_53633_70	SARG|gi|445996724|ref|WP_000074579.1|	30.8	260	294	309	3.50e-25	101
k141_53633_70	SARG|gi|884875933|emb|CKG93789.1|	30.8	260	294	309	3.50e-25	101
k141_53633_70	SARG|gi|445996722|ref|WP_000074577.1|	30.8	260	294	309	3.50e-25	101
k141_53633_70	SARG|gi|446110087|ref|WP_000187942.1|	30.0	260	294	309	4.86e-25	100
k141_53633_70	SARG|gi|445996710|ref|WP_000074565.1|	30.0	260	294	309	6.73e-25	100
k141_53633_74	SARG|gi|542061059|gb|ERI11611.1|	25.0	268	503	316	1.81e-19	88.2
k141_53633_74	SARG|P42332	24.7	219	503	306	1.74e-18	85.1
k141_53633_74	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	24.7	219	503	306	1.74e-18	85.1
k141_53633_74	SARG|gi|510143239|gb|AGN36970.1|	24.7	219	503	313	1.91e-18	85.1
k141_53633_74	SARG|YP_001373621	24.5	274	503	318	2.04e-18	85.1
k141_53633_74	SARG|ABB80128	24.7	219	503	306	2.35e-18	84.7
k141_53633_74	SARG|AAD21213	24.7	219	503	306	5.78e-18	83.6
k141_53633_74	SARG|gi|695701476|ref|WP_032638992.1|	26.3	247	503	646	2.28e-15	77.8
k141_53633_74	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.9	233	503	664	2.21e-14	74.7
k141_53633_74	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.0	184	503	362	1.24e-11	65.1
k141_53633_76	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.0	112	535	219	1.70e-06	48.1
k141_53633_76	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	24.4	123	535	228	2.49e-06	47.8
k141_53633_98	SARG|P42332	26.4	227	223	306	1.34e-16	75.9
k141_53633_98	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	26.4	227	223	306	1.34e-16	75.9
k141_53633_98	SARG|gi|510143239|gb|AGN36970.1|	26.4	227	223	313	1.43e-16	75.9
k141_53633_98	SARG|AAD21213	26.4	227	223	306	1.84e-16	75.5
k141_53633_98	SARG|ABB80128	26.4	227	223	306	2.53e-16	75.1
k141_53633_98	SARG|YP_001373621	25.9	228	223	318	2.55e-15	72.4
k141_53633_98	SARG|gb|AAR96051.1|ARO:3002894|otrC	26.4	87	223	351	1.50e-06	47.0
k141_53633_98	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	26.4	87	223	351	1.50e-06	47.0
k141_53633_102	SARG|ZP_04679156	27.7	451	466	451	1.66e-38	144
k141_53633_102	SARG|gb|CAE00499.1|ARO:3003835|cdeA	26.7	439	466	441	1.37e-30	122
k141_53633_102	SARG|HE999704.1.gene3064.p01	31.0	210	466	241	1.12e-17	81.3
k141_53633_102	SARG|gi|441475675|emb|CCQ25429.1|	32.7	168	466	211	3.85e-13	67.4
k141_179411_11	SARG|gi|686123390|ref|WP_031769354.1|	25.3	439	452	451	5.14e-40	148
k141_179411_11	SARG|gi|516415429|ref|WP_017804827.1|	25.5	435	452	451	1.36e-39	147
k141_179411_11	SARG|gi|487138435|ref|WP_001629863.1|	25.3	439	452	451	1.36e-39	147
k141_179411_11	SARG|gi|686367913|ref|WP_031894914.1|	25.1	439	452	451	1.87e-39	146
k141_179411_11	SARG|gi|686309068|ref|WP_031870147.1|	25.5	435	452	451	1.87e-39	146
k141_179411_11	SARG|gi|686432388|ref|WP_031921070.1|	25.3	439	452	451	2.59e-39	146
k141_179411_11	SARG|gi|486285962|ref|WP_001572033.1|	25.1	439	452	451	2.59e-39	146
k141_179411_11	SARG|gi|686396521|ref|WP_031908504.1|	25.1	439	452	451	3.57e-39	145
k141_179411_11	SARG|ZP_03986195	25.1	439	452	451	3.57e-39	145
k141_179411_11	SARG|Q99WP2	25.1	439	452	451	3.57e-39	145
k141_179411_12	SARG|gi|313638554|gb|EFS03703.1|	26.2	442	458	453	7.44e-38	142
k141_179411_12	SARG|gi|505177635|ref|WP_015364737.1|	24.5	436	458	451	9.35e-37	139
k141_179411_12	SARG|ZP_04679156	24.3	436	458	451	5.88e-35	134
k141_179411_12	SARG|gi|488374619|ref|WP_002444004.1|	22.8	435	458	452	8.20e-35	134
k141_179411_12	SARG|gi|313614636|gb|EFR88215.1|	26.1	449	458	453	8.32e-35	134
k141_179411_12	SARG|gb|CAE00499.1|ARO:3003835|cdeA	21.8	426	458	441	2.08e-27	112
